Thermo Fisher Launches Olink® Target 48 Panel To Advance Neurodegeneration Research, Offers Absolute Quantification Of 41 Protein Biomarkers

Thermo Fisher Scientific Inc., the global leader in serving science, has launched the Olink® Target 48 Neurodegeneration panel, a high-performance proteomics immunoassay designed to accelerate biomarker discovery in neurodegenerative disease research. With the rising prevalence of Alzheimer’s, Parkinson’s, multiple sclerosis, and other conditions, researchers face urgent needs for scalable and reproducible protein measurement. The panel measures 41 key and emerging protein biomarkers with absolute quantification using just 1µL of plasma sample.

An early access user, Charlotte Teunissen, professor in neurochemistry at the Department of Laboratory Medicine at Amsterdam University Medical Centre, shared, “The Target 48 Neurodegeneration panel is a critical tool that enables the detection and quantification of key and emerging neurodegenerative disease biomarkers from plasma and cerebrospinal fluid samples. By generating quantitative data, it ensures reproducible results across and within longitudinal studies, moving a step forward towards clinical utilisation.”

This new panel joins Olink’s growing suite of targeted proteomic solutions, including the Olink® Target 48 Cytokine, Olink® Target 48 Immune Surveillance, and the Olink® Flex platform. Together, these tools create a robust ecosystem that enables comprehensive analysis of protein biomarkers linked to neurodegeneration and inflammation. By combining multiple panels, scientists can gain deeper insights into disease pathways and accelerate translational research.

"Neurological diseases are complex, multifactorial and urgently in need of translational insights, especially with non-invasive proteomic biomarkers for longitudinal monitoring. The panel, designed in close collaboration with leading clinical researchers, offers absolute quantification of multiplex key biomarkers to monitor disease progression and therapeutic responses to power precision medicine," said Yan Zhang, President of the Proteomic Sciences business at Thermo Fisher Scientific. 

Built on Olink’s Proximity Extension Assay (PEA) technology, the panel delivers scalability, reproducibility across global labs, and compatibility with the Olink® Signature Q100 system. It also minimises import challenges by reducing reliance on plasma-derived products and offers streamlined workflows for multi-centre trials. With this launch, Thermo Fisher strengthens its commitment to advancing precision medicine, neuroscience research, and large-scale biobank studies through innovative proteomics solutions.